Treos Bio   Report issue

For profit Phase 2
Founded: London United Kingdom (2013)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2018
NCT03391232
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Treos Bio Limited | Treos Bio Ltd. | Treos Bio Zrt

Active Ingredients

Drugs in Phase 2 Trials (2)

atezolizumab (Tecentriq) (1 trial)

polypepi1018 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2